Breaking News

Ligand Licenses Captisol-Enabled Ganaxolone

Marinus has exclusive worldwide rights to Captisol-enabled ganaxolone for use in humans

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals Inc. has entered into commercial License and Supply Agreements with Marinus Pharmaceuticals, Inc., granting rights to use Captisol in the formulation of its intravenous (IV) ganaxolone. Captisol is a chemically modified cyclodextrin designed to optimize the solubility and stability of drugs. Marinus will initiate clinical trials with Captisol-enabled ganaxolone IV in patients with postpartum depression (PPD) and status epilepticus (SE).   This License Agreement replaces ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters